AI Article Synopsis
- - There is currently no standard treatment for metastatic uveal melanoma (mUM), making management of the disease challenging.
- - Although immunotherapy is frequently utilized for mUM, it has not been tested in large phase III clinical trials with checkpoint inhibitors, and only a small percentage of patients benefit from it.
- - Researchers reviewed the immunological characteristics of mUM to explore whether immunotherapy might still be effective in treating this type of cancer.
Article Abstract
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721347 | PMC |
| http://dx.doi.org/10.3390/cancers11081055 | DOI Listing |
Publication Analysis
Top Keywords
uveal melanoma
8
immunological backbone
4
backbone uveal
4
melanoma rationale
4
rationale immunotherapy?
4
immunotherapy? standard
4
standard treatment
4
treatment established
4
established metastatic
4
metastatic uveal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!